PCRX Financials Pacira Biosciences, Inc.

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Jun 29, 2026, 13:10 UTC Overview →

Growth & profitability

Revenue has grown 11.1% per year over the past 5 years.
Net income has grown slower than revenue (-45.5% vs 11.1% per year).
Operating margin has contracted, at 2.6% in the latest year.
Free cash flow has grown 28.4% per year over the past 5 years.

Financial health

Total debt ($372M) exceeds cash ($159M); net debt is $214M.
Total debt has grown slower than revenue (-18.6% vs 11.1% per year).
Operating income covered interest expense 1.1× in the latest year.
Total debt is 3.4× EBITDA.

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key annual figures

FY	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
2025	$726M	$7M	79.4%	2.6%	1.0%	0.6%	$137M	$372M	$159M
2024	$701M	-$100M	75.7%	-10.5%	-12.8%	-6.4%	$179M	$585M	$277M
2023	$675M	$42M	72.6%	13.0%	4.8%	2.7%	$139M	$522M	$153M
2022	$667M	$16M	70.1%	9.0%	2.1%	0.9%	$115M	$689M	$104M
2021	$542M	$42M	74.1%	16.6%	5.8%	2.0%	$80M	—	$586M
2020	$430M	$146M	72.7%	10.8%	23.5%	11.4%	$39M	—	$100M
2019	$419M	-$11M	74.5%	2.5%	-3.1%	-1.3%	$60M	—	$78M
2018	$332M	-$471000	73.9%	4.8%	-0.1%	-0.1%	$34M	—	$133M
2017	$284M	-$43M	69.1%	-8.8%	-15.2%	-6.8%	-$1M	—	$54M
2016	$270M	-$38M	59.2%	-11.9%	-17.3%	-9.7%	—	$109M	$36M
2015	—	$2M	—	—	0.8%	0.5%	—	$104M	$54M
2014	—	-$14M	—	—	-8.0%	-4.2%	—	$103M	$38M
2013	—	-$64M	—	—	-154.9%	-37.6%	—	$99M	$13M
2012	—	-$52M	—	—	-79.4%	-46.7%	—	$25M	$13M
2011	—	-$43M	—	—	-89.8%	-38.2%	—	$26M	$46M

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex, quarterly)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key quarterly figures

Quarter	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
Mar '26	$177M	$3M	79.5%	3.9%	0.4%	0.2%	$23M	$368M	$144M
Dec '25	$197M	$2M	79.5%	1.2%	0.2%	0.1%	$43M	$372M	$159M
Sep '25	$180M	$5M	80.9%	3.5%	0.7%	0.4%	$57M	$377M	$148M
Jun '25	$181M	-$5M	77.4%	4.7%	-0.6%	-0.3%	$9M	$580M	$300M
Mar '25	$169M	$5M	79.7%	1.2%	0.6%	0.3%	$27M	$583M	$284M
Dec '24	$187M	$16M	78.7%	13.2%	2.1%	1.0%	$31M	$585M	$277M
Sep '24	$169M	-$143M	76.9%	-82.8%	-19.1%	-9.4%	$50M	—	$246M
Jun '24	$178M	$19M	75.1%	15.9%	2.1%	1.1%	$52M	—	$247M
Mar '24	$167M	$9M	71.6%	7.9%	1.0%	0.6%	$46M	—	$184M
Dec '23	$181M	$25M	73.7%	18.3%	2.9%	1.6%	$46M	$522M	$153M
Sep '23	$164M	$11M	75.8%	10.8%	1.3%	0.7%	$41M	—	$99M
Jun '23	$169M	$26M	71.6%	23.5%	3.2%	1.7%	$40M	—	$87M
Mar '23	$160M	-$20M	69.4%	-1.9%	-2.5%	-1.3%	$13M	—	$36M
Dec '22	$172M	-$10M	64.0%	-5.8%	-1.3%	-0.6%	$37M	$689M	$104M
Sep '22	$167M	-$693000	69.7%	12.7%	-0.1%	-0.0%	$37M	—	$109M
Jun '22	$169M	$20M	70.1%	18.4%	2.6%	1.1%	$18M	—	$122M
Mar '22	$158M	$7M	77.2%	11.0%	1.0%	0.4%	$23M	—	$227M
Dec '21	$159M	-$5M	75.5%	2.6%	-0.7%	-0.2%	$14M	—	$586M
Sep '21	$128M	$18M	72.9%	24.6%	2.5%	1.3%	$47M	—	$134M
Jun '21	$136M	$19M	74.0%	25.7%	2.8%	1.4%	$20M	—	$106M

Valuation over time

How the market has priced PCRX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

The price-to-earnings ratio has risen from 102.2× (Mar '23) to 207.3× (Nov '26).
The price-to-sales ratio has fallen from 2.4× (Mar '23) to 2.0× (Nov '26).

Price / earnings (P/E)

P/E

Price / sales (P/S)

P/S

Frequently asked questions

Is PCRX growing its revenue and profit?

Over the past 5 years, Pacira Biosciences, Inc.'s revenue has grown 11.1% per year, and net income declined 45.5% per year. These are computed facts, not advice.

How much debt does PCRX have?

As of FY2025, Pacira Biosciences, Inc. reported $372M of total debt against $159M of cash; operating income covered interest expense 1.1×.

What is PCRX's profit margin?

In FY2025, gross margin was 79.4%, operating margin 2.6%, and net margin 1.0%.

What is PCRX's P/E ratio?

Pacira Biosciences, Inc.'s P/E (TTM) is 99.12 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the PCRX stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 207.3× as of Nov '26) can differ. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.